ByErika Edwards
Scientists say a COVID-19 vaccine candidate has shown it can prompt an immune response in the human body, and was also found to be safe and well-tolerated in a small group of patients.
Cambridge, Massachusetts-based Moderna manufacturer of the vaccine, announced the encouraging early results from its phase 1 clinical trial Monday morning. The drug is now being tested in larger studies.
Moderna's phase 1 trial involved 45 people. Results on eight of those participants revealed they developed neutralizing antibodies — which are believed to be key in providing protection from the virus — at levels seen in patients who've recovered from COVID-19.
Read the full story: NBCNews.com
See the Moderna release here.